[1] Xu B, et al. DAWNA-1 Study Consortium. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021 Nov;27(11):1904-1909.
[2] Zhang P, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. Published online May 11, 2023.[3] Fan Y, Sun T, Shao ZM, et al. Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Aug 26;e213428. doi: 10.1001/jamaoncol.2021.3428.[4] Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol,2019,20(6):806-815[5] Xu B, et al, Acta Pharmaceutica Sinica B 2023;13(5):2250e2258[6] Xu B, Sun T, Zhang O, et al. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline-and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial[J]. Annals of oncology: official journal of the European Society for Medical Oncology,2021,32(2):218-228.[7] Fan Y, Xu B. Ann Oncol, 2014.[8] Hu XC, et al. Lancet Oncol. 2015 Apr;16(4):436-462.[9] Zhang J, et al. Ann Oncol. 2018 Aug 1;29(8):1741-1747[10] Yu K, Ye F, He M, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(9):1390–1396. doi:10.1001/jamaoncol.2020.2965[12] Wang SS, et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment. JAMA, 2020. DOI:10.1001/jama.2020.23370P[15] Xu B, et al. Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the phase III EVER-002 study.2023 ESMO asia abstracts LBA4.[16] Xu B, et al.2024 ASCO abstract104.[17] Ma F, LiQ,Xu B, et al. J Clin Oncol, 2017.[18] Ma F, Xu B , et al.JClin Oncol.2019[19] Xu B, et al. Lancet Oncol. 2021 Mar;22(3):351-360[20] Ma F,et al. BMJ.2023 0ct 31:383:e076065.